Packaging and tiers for Series A companies: the 90-day install for healthcare and life sciences in the Middle East
The exact 90-day plan for standing up packaging and tiers at Series A — the point where the founder can no longer be every function. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Middle East.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install packaging and tiers has to be shaped to that reality from day one.
Series A is the moment packaging and tiers stops being optional. The founder has to step out of some of the work, the plan requires a defensible growth number, and every quarter compounds toward the next raise.
Day 1 to 30: diagnosis and instrumentation. Name the constraint, write the ICP, wire average contract value by tier into the board pack.
Day 31 to 60: first live cycle at 20% of planned volume. Founder still in every review. Kill criteria written and enforced.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Packaging and tiers is only useful here when it is pointed at both constraints at once.
Day 61 to 90: ramp to full volume, hire the first dedicated operator, and hand off ops. Founder retains strategy and the weekly review.
By day 90 the metric is legible and the trajectory is defensible. This is what turns a Series A story into a Series B round.
Trap most Series A companies fall into: three tiers labelled small, medium, large that mean nothing. It usually shows up around day 45 when the founder tries to hire ahead of the model.
The Series A version of packaging and tiers looks small compared to what you will build at Series B. That is the point — it is a foundation, not a monument.
Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing packaging and tiers deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Pricing · healthcare · Middle East — answered
- Does packaging and tiers work for healthcare and life sciences in the Middle East?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The healthcare teams that install this get past procurement instead of dying in it.
- Should we start packaging and tiers before Series A?
- Yes if the founder has time; the Series A version is the same model at higher spend.
- How much of the round should fund packaging and tiers?
- Meaningful — often 20–30% of the growth line — but only after diagnosis.
- When do we hire the first packaging and tiers operator?
- Around day 60, once the model has run one full cycle with the founder.
- What Series A trap should we avoid?
- Three tiers labelled small, medium, large that mean nothing — usually a premature senior hire.
- What is the Middle East-specific pitfall when running packaging and tiers for healthcare?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under pricing · healthcare · middle east